£700K
The pre-seed round features backing from Vine Ventures and Lionheart Ventures alongside UK angels.
"Psychedelic assisted therapy could be ground-breaking for mental health treatment, and the UK is well-placed to be at the vanguard of that as a global leader in clinical trials post-Brexit. Clerkenwell Health’s aim is to establish the UK as the heart of the commercial psychedelic research ecosystem, working closely with mental health experts and drug developers around the world to tackle some of the most complex mental health conditions."